Dernières nouvelles pour INVO Bioscience (NASDAQ:INVO) Stock

INVO Bioscience

INVO Bioscience Inc operates a healthcare services fertility company. Assisted Reproductive Technology (ART) marketplace by making fertility care more accessible and inclusive to people. Its commercial strategy is focused on operating fertility-focused clinics, which includes the opening of dedicated INVO Centers offering the INVOcell and IVC procedure (with three centers in North America now operational) and the acquisition of US-based, profitable in vitro fertilization (IVF) clinics. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.

INVO Bioscience Inc

InvoCare Ltd

News

Management

JYNT

The Joint Corp Appoints Sanjiv Razdan As Its President And CEO, Effective Today; Peter Holt Resigns

September production decreased by approximately&nbsp;2%&nbsp;month over month from August (19.7 BTC mined) due to the increase in the bitcoin difficulty level which peaked at 92.67 in September vs. 90.67 in August 2024.
&nbsp;

GRYP

Gryphon Digital Mining Releases Operational Update For September; Expect To Have Generated Revenues Of $1.16M For September, Based On An Average Bitcoin Price Of $60,286

Investors interested in Furniture stocks are likely familiar with Flexsteel Industries (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flxs#NASDAQ">FLXS</a>) and SharkNinja, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sn#NYSE">SN</a>). But which of these two stocks presents investors with the better value opportunity right now? Let&#39;s take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Flexsteel Industries and SharkNinja, Inc. are both sporting a Zacks Rank of # 1 (Strong Buy) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. But this is just one piece of the puzzle for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
FLXS currently has a forward P/E ratio of 13.79, while SN has a forward P/E of 25.42. We also note that FLXS has a PEG ratio of 1.15. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company&#39;s expected earnings growth rate. SN currently has a PEG ratio of 1.72.
Another notable valuation metric for FLXS is its P/B ratio of 1.42. Investors use the P/B ratio to look at a stock&#39;s market value versus its book value, which is defined as total assets minus total liabilities. By comparison, SN has a P/B of 9.12.
Based on these metrics and many more, FLXS holds a Value grade of A, while SN has a Value grade of D.
Both FLXS and SN are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that FLXS is the superior value option right now.
<a href="https://www.zacks.com/stock/news/2350085/flxs-or-sn-which-is-the-better-value-stock-right-now?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2350085">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Small Cap

Markets

Analyst Ratings

Tech

Trading Ideas

FLXS

FLXS or SN: Which Is the Better Value Stock Right Now?

SGHT

Sight Sciences Reports Publication Of New Study Titled, Impact Of TearCare On Reading Speed In Patients With Dry Eye Disease In The Peer-reviewed Journal Clinical Ophthalmology

WIIM

PHX Minerals shares are trading higher after the company announced WhiteHawk Energy sent a letter regarding its acquisition proposal.

Blink is offering a solution for former Enel X and JuiceBox customers to power up their EV charging with Blink.&nbsp;
All customers need to do is prepare their site, and Blink will handle the rest. Additionally, if you already have a JuiceBox charging station but need an upgrade, Blink will swap it out for free.

BLNK

Blink Charging Steps In To Support EV Charging Station Hosts Affected By Enel X's Recent Decision To Close Its North American Operations

Investors interested in stocks from the Financial - Investment Management sector have probably already heard of Victory Capital Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vctr#NASDAQ">VCTR</a>) and SEI Investments (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seic#NASDAQ">SEIC</a>). But which of these two stocks offers value investors a better bang for their buck right now? We&#39;ll need to take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Victory Capital Holdings and SEI Investments are both sporting a Zacks Rank of # 2 (Buy) right now. Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions. However, value investors will care about much more than just this.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
VCTR currently has a forward P/E ratio of 11.12, while SEIC has a forward P/E of 16.52. We also note that VCTR has a PEG ratio of 0.61. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company&#39;s expected earnings growth rate. SEIC currently has a PEG ratio of 1.38.
Another notable valuation metric for VCTR is its P/B ratio of 3.36. The P/B ratio pits a stock&#39;s market value against its book value, which is defined as total assets minus total liabilities. For comparison, SEIC has a P/B of 4.05.
These metrics, and several others, help VCTR earn a Value grade of B, while SEIC has been given a Value grade of C.
Both VCTR and SEIC are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that VCTR is the superior value option right now.
<a href="https://www.zacks.com/stock/news/2350084/vctr-vs-seic-which-stock-is-the-better-value-option?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2350084">To read this article on Zacks.com click here.</a>

Mid Cap

SEIC

VCTR

VCTR vs. SEIC: Which Stock Is the Better Value Option?

Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) and the Department of Culture and Tourism – Abu Dhabi announced that they will work together to bring the world's second Sphere to Abu Dhabi, United Arab Emirates. This next-generation entertainment medium is expected to be a landmark addition to this premier international capital city, elevating the entertainment offerings for residents and visitors alike.

Global

SPHR

Sphere Entertainment And The Department Of Culture And Tourism – Abu Dhabi Announce Plans To Make Abu Dhabi Next Sphere Venue Location

MDAI

Spectral AI shares are trading higher after the company announced it named its founder Dr. J. Michael DiMaio as the Chairman.

Spectral AI Names Founder Dr. J. Michael DiMaio As Chairman

<a href="https://pr.report/3i0a">Gryphon Digital Mining</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) ("Gryphon" or the "Company"), a bitcoin mining company that is focused on low-cost, efficient operations, has released its unaudited operational update for September 2024.
Key September 2024 highlights:
Steve Gutterman Named as Chief Executive Officer, Jimmy Vaipoulos as Chairman and Sim Salzman to continue as Chief Financial Officer
+500 MW power pipeline: Gryphon continues to evaluate a pipeline of similar low-cost opportunities for potentially +500 MW
Improved Hashrate: Monthly average hashrate of 920 PH/s, a 4% increase over August 2024
Bitcoin Production: Expect to have produced approximately 19.31 bitcoin
Projected approximately $1.16 million in value based on an average bitcoin price for the month of $60,286
High Uptime: 98.7% mining fleet average up time in September following 97.3% in August due to maintenance
Sustainable Operations: Scope 1 and Scope 21 operations at our Northeastern U.S. operations continue to be 100% electrified by zero-carbon emitting hydro power

Gryphon Digital Mining Announces September Operational Update; Expect To Have Produced ~19.31 Bitcoin

The letter includes details of the extensive efforts WhiteHawk has made over the past 18 months to engage with PHX to maximize value for stockholders through a transaction.
Urges the PHX Board of Directors to engage with WhiteHawk to pursue and complete a transaction following unwillingness to engage over the past 18 months

WhiteHawk Energy Sends Letter To PHX Minerals Chairman Mark Behrman With Respect To Its $4.00 Per Share Proposal

<a href="https://patentcenter.uspto.gov/applications/17677698/ifw/docs" title="https://patentcenter.uspto.gov/applications/17677698/ifw/docs">https://patentcenter.uspto.gov/applications/17677698/ifw/docs</a>

Biotech

General

HOTH

Hoth Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 17/677,698 Titled "USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE".

Former Congressman Joe Garcia, who represented Florida's 26th congressional district, has voiced strong support for the cannabis legalization measure, known as <a href="https://www.benzinga.com/markets/cannabis/24/04/38034138/florida-supreme-court-approves-cannabis-legalization-proposal-for-november-election-in-blow-to-d" target="_blank" rel="noreferrer noopener">Amendment 3</a>, that will appear on the ballot in the <a href="https://www.benzinga.com/topic/2024-election">upcoming November elections</a>
"One of the most compelling reasons to support Amendment 3 is the growing body of research that suggests marijuana acts as an exit substance, not a gateway drug," said Garcia in a <a href="https://www.miamiherald.com/opinion/article293689854.html">Miami Herald</a> opinion piece. "Contrary to outdated beliefs, numerous studies have shown that marijuana can help individuals reduce their dependence on more harmful substances, including prescription opioids."
He pointed out that the illicit market poses risks, including reports of marijuana being laced with dangerous substances like <a href="https://www.benzinga.com/topic/fentanyl">fentanyl</a>. By regulating the market, Florida could ensure that consumers have access to safe, lab-tested products, he said.
Garcia also addressed concerns about teenage cannabis use. "Research indicates that in states where marijuana is legal, teen use rates have actually declined. This is likely due to the stringent regulations and safeguards that come with legalization, making it more difficult for underage individuals to access marijuana."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41250277/miami-herald-endorses-florida-cannabis-legalization-highlights-failed-drug-war-revenue-potential">Miami Herald Endorses Florida Cannabis Legalization, Highlights Failed Drug War, Revenue Potential</a>
<h2 class="wp-block-heading">And Then There's The Money</h2>
Estimates suggest that legalized marijuana could generate up to $431 million annually in new tax revenue in Florida.
"This influx of funds could be directed toward essential public services such as education, healthcare and infrastructure. Imagine the positive impact on our schools, hospitals and roads with this additional revenue stream. It's an opportunity to invest in our future and improve the quality of life for all Floridians," Garcia wrote.
This new source of income, he said, could have a transformative impact on the state.
"We have fewer individual freedoms and we are passing up millions in tax revenue, tourism dollars and market growth that will create new jobs right here in Florida. Amendment 3 is not just about legalizing marijuana; it's about adopting a sensible, evidence-based approach to drug policy."
Garcia is a paid advisor for the organization <a href="https://drupal-cloudfront.benzinga.com/topic/smart-and-safe-florida" target="_blank" rel="noreferrer noopener">Smart and Safe Florida</a>, which helped get Amendment 3 on the ballot.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41303141/fact-check-desantis-why-floridas-weed-legalization-does-not-mean-smoking-in-schools">Fact-Check DeSantis: Why Florida&#8217;s Weed Legalization Does Not Mean Smoking In Schools</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Cannabis

Regulations

Politics

Legal

Florida Cannabis Legalization Gains Support From Former Congressman, Citing Economic Growth, Public Health

Editor&#8217;s note: This article was updated to correctly state the title of the CCO and co-founder of Cornbread Hemp.
A California judge has denied a temporary restraining order (TRO) filed by national hemp advocates and businesses, including <a href="https://www.benzinga.com/markets/cannabis/24/10/41196739/cheech-and-chong-cannabis-company-hemp-roundtable-petition-court-to-stop-gov-newsoms-controversi">Cheech and Chong's Global Holdings</a>, aimed at blocking the state's controversial ban on hemp products with detectable levels of THC. 
The TRO, which was requested as part of a lawsuit filed last month by the U.S. Hemp Roundtable and several hemp companies, sought to halt the enforcement of the new regulations until the case could be fully heard. 
However, the judge sided with the state and Gov. Gavin Newsom, allowing the ban to remain in place.
<h3 class="wp-block-heading">Emergency Regulations Banning Hemp</h3>
The <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">emergency regulations</a>, which went into effect on September 23, prohibit the sale of consumable hemp products with any detectable delta-9 THC or intoxicating cannabinoids like delta-8 THC in California. 
These regulations also limit hemp products to five servings per package and restrict sales to individuals aged 21 and over. 
Hemp advocates argue that this will severely impact the industry, especially businesses producing non-intoxicating hemp products that provide therapeutic benefits to consumers.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41124583/californias-new-hemp-rules-could-reshape-cannabis-a-different-set-of-rules-in-every-state">California&#8217;s New Hemp Rules Could Reshape Cannabis: &#8216;A Different Set Of Rules In Every State&#8217;</a>
<h3 class="wp-block-heading">Industry Reacts</h3>
The ruling prompted strong reactions. 
&#8220;Today, a judge sided against common sense and in favor of Gov. Newsom. The judge's ruling to deny a temporary restraining order against Newsom's hemp products ban announces that Californians will lose access to USDA-certified organic hemp products in retail stores across the state,&#8221; Jim Higdon, CCO and co-founder of <a href="https://www.benzinga.com/markets/cannabis/24/09/40833963/expert-calls-for-a-united-hemp-and-cannabis-front-industries-should-collaborate-and-push-for-fed">Cornbread Hemp </a>and a member of the U.S. Hemp Roundtable, told Benzinga Cannabis in an email.
&#8220;At a time when the California cannabis dispensary system is undergoing a credibility crisis due to pesticide contamination, the governor has made it much more difficult for Californians to access the only cannabis products that consumers can be certain are free of pesticides – USDA-certified organic hemp products with third-party lab tests,&#8221; Higdon said.
The legal battle is set to continue, as the case moves forward, with the hemp industry determined to challenge the ban's legality in court.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">Gov. Newsom&#8217;s Hemp Ban Goes Into Effect: Consequences For Industry, Investors, Patients</a></li>
</ul>
Cover: AI Generated Image

Government

California Judge Rules Gov. Newsom's Hemp Ban Stands Despite Industry Pushback (Corrected)

HubSpot, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hubs#NYSE">HUBS</a>) recently inked a definitive agreement to acquire Cacheflow, an industry leader in B2B subscription billing management and configure, price, quote (CPQ) solution, for an undisclosed amount. Cacheflow will operate as HUBS&#39; wholly owned subsidiary following the completion of the buyout.
Cascheflow&#39;s AI native billing and subscription management solution is designed to streamline software buying and selling processes in a B2B space. The solution provides a unified, no-code platform for automating the SaaS sales flow.
In 2023, HubSpot introduced Commerce Hubs&#39; on its smart CRM (Customer Relationship Management) to simplify various processes such as invoicing and payments. HUBS&#39; Commerce Hub offering has gained solid market traction over the past year. With this acquisition, the company is aiming to further strengthen Commerce Hubs&#39; functionalities and enhance its prospects across industries.
Cacheflow&#39;s portfolio will make the quote-to-cash process easier, thereby simplifying the buying process and boosting customer satisfaction. It will also strengthen HUBS&#39; ability to address areas such as upselling, renewals and other commerce functions. Automation of subscription billing and CPQ will enable businesses to close deals faster and expedite revenue collection. A seamless purchasing process will also enhance customer retention. This will also bolster Commerce HUBS&#39; capabilities in managing clients and transaction data, enhancing enterprises&#39; visibility and decision-making.
<h2>Will This Buyout Drive HUBS&#39; Share Performance?</h2>
Customers appreciate flexibility and customization during product purchases. However, ensuring this in a legacy CPQ system, which involves several steps for product configuration, quote generation and pricing changes, is a time-consuming endeavor. This outdated billing and payment system leads to lengthy sales cycles and inefficient revenue collection. To tackle these challenges, enterprises are increasingly looking for a solution to automate key components of revenue management and enhance customer experience.
The subscription and billing management market is projected to grow at a substantial rate in the upcoming years. By integrating Cacheflow&#39;s AI-powered capabilities into Commerce Hub, HUBS is aiming to capitalize on these evolving market trends. The buyout will augment HubSpot&#39;s ability to address the complete commerce cycle for enterprises. This bodes well for long-term growth.
<h2>HUBS Stock&#39;s Price Performance</h2>
Shares of HubSpot have gained 19.2% over the past year compared with the industry&#39;s 43% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a5/81144.jpg?v=375653989" />
Image Source: Zacks Investment Research
<h2>HUBS&#39; Zacks Rank and Key Picks</h2>
HubSpot currently carries a Zacks Rank #3 (Hold).
Zillow Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zg#NASDAQ">ZG</a>) carries a Zacks Rank #2 (Buy) at present. In the last reported quarter, it delivered an earnings surprise of 25.81%.
ZG delivered an earnings surprise of 37.41%, on average, in the trailing four quarters. The company is witnessing solid momentum in rental revenues, driven by growth in both multi and single-family listings, which is a positive factor.
Ubiquiti Inc.&nbsp;sports a Zacks Rank of 1 at present. The company offers a comprehensive portfolio of networking products and solutions for service providers and enterprises.
Its excellent global business model, which is flexible and adaptable to evolving changes in markets, helps it to beat challenges and maximize growth. The company&#39;s effective management of its strong global network of more than 100 distributors and master resellers improved its UI&#39;s visibility for future demand and inventory management techniques.
Workday Inc.&nbsp;sports a Zacks Rank of 1 at present. In the last reported quarter, it delivered an earnings surprise of 7.36%.
WDAY is a leading provider of enterprise-level software solutions for financial management and human resource domains. The company&#39;s cloud-based platform combines finance and HR in a single system that makes the process easier for organizations to provide analytical insights and decision support.
<a href="https://www.zacks.com/stock/news/2350075/hubspot-boosts-portfolio-with-strategic-buyout-will-the-stock-gain?cid=CS-BENZ-FT-analyst_blog|company_news_tech_sector-2350075">To read this article on Zacks.com click here.</a>

Offerings

HUBS

HubSpot Boosts Portfolio With Strategic Buyout: Will the Stock Gain?

This transaction vertically integrates Bit Digital&#39;s HPC operations with an existing, fully operational and fully leased Tier 3 datacenter in a major city; provides a strong diversity of existing and prospective colocation customers; delivers a strong pipeline of expansion site opportunities and an experienced team to lead the development processes; and enables Bit Digital to offer new service offerings such as colocation and on-demand computing to complement its existing GPU offerings.
Bit Digital has acquired Enovum for a total consideration of CAD&nbsp;$62.8MM (approximately USD $46MM based on a CAD/USD exchange rate of 0.73).&nbsp;The transaction closed on&nbsp;October 11, 2024.

BTBT

Bit Digital Acquires Enovum Data Centers For Total Consideration Of Approximately $46M

Belpointe PREP Reports Hurricane Milton Inflicted No Significant Damage

Ratings for Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $252.89, a high estimate of $285.00, and a low estimate of $220.00. This current average has increased by 8.69% from the previous average price target of $232.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1728936070_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Insulet among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$269.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$234.00</td>
<td>$234.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insulet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Insulet's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Insulet's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insulet analyst ratings.</a>
<h2>Delving into Insulet's Background</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>A Deep Dive into Insulet's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Insulet's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.2% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Insulet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Insulet's ROE excels beyond industry benchmarks, reaching 21.08%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 6.85%, the company showcases effective utilization of assets.
Debt Management: Insulet's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.4, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PODD

Analyst Ratings For Insulet

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Churchill Downs, revealing an average target of $161.82, a high estimate of $166.00, and a low estimate of $155.00. Witnessing a positive shift, the current average has risen by 5.02% from the previous average price target of $154.09.
<img src="https://www.benzinga.com/files/images/story/2024/1728936060_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Churchill Downs among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$166.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Shaun Kelley</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$166.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$157.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Jeffrey Stantial</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$164.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$166.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$161.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Jeffrey Stantial</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$158.00</td>
<td>$156.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Churchill Downs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Churchill Downs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Churchill Downs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Churchill Downs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CHDN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Churchill Downs analyst ratings.</a>
<h2>Unveiling the Story Behind Churchill Downs</h2>
Churchill Downs Inc is a gaming entertainment, online wagering, and racing company. It operates through three business segments: Live and Historical Racing, TwinSpires, and Gaming. The Live and Historical Racing segment includes live and historical pari-mutuel racing. The TwinSpires segment includes the revenue and expenses for online horse racing and the online and retail sports betting and iGaming wagering business. The Gaming segment includes revenue and expenses for the casino properties and associated racetracks that support the casino license. The Gaming segment generates revenue and expenses from slot machines, table games, video lottery terminals, video poker, HRMs, ancillary food and beverage services, hotel services, commission on pari-mutuel wagering, and racing events.
<h3>Churchill Downs: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Churchill Downs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.9% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Churchill Downs's net margin is impressive, surpassing industry averages. With a net margin of 23.5%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Churchill Downs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 22.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Churchill Downs's ROA excels beyond industry benchmarks, reaching 2.94%. This signifies efficient management of assets and strong financial health.
Debt Management: Churchill Downs's debt-to-equity ratio is below the industry average at 4.71, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHDN

Where Churchill Downs Stands With Analysts

APP, MGNX and CYCC among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
INVO Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) just reported results for the first quarter of 2024.<ul><li>INVO Bioscience reported earnings per share of -42 cents.</li><li>The company reported revenue of $1.58 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/invo-stock-earnings-invo-bioscience-for-q1-of-2024/">INVO Stock Earnings: INVO Bioscience Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INVO Stock Earnings: INVO Bioscience Reported Results for Q1 2024

INVO BioScience reports Q1 results

MGNI, VERV and GWAV among pre-market gainers

GoodRx Holdings, Seelos Therapeutics, Clever Leaves among healthcare movers

INVO Bioscience files for $100M mixed shelf

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!



Moving stocks this morning are clinical trial updates, an acquisition deal and a public offering.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Planet Image (NASDAQ:<a href="https://investorplace.com/stock-quotes/yibo-stock-quote/">YIBO</a>) stock is rocketing more than 79% alongside heavy pre-market trading.</li>



<li>Lipella Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/lipo-stock-quote/">LIPO</a>) shares are soaring over 58% after <a href="https://www.stocktitan.net/news/LIPO/lipella-pharmaceuticals-initiates-phase-2a-trial-for-lp-310-in-oral-kdvluw7gmnv7.html">initiating a Phase 2a clinical trial</a>.</li>



<li>Cognition Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgtx-stock-quote/">CGTX</a>) stock is surging more than 44% with <a href="https://www.nasdaq.com/press-release/cognition-therapeutics-proof-concept-phase-2-shine-trial-demonstrates-consistent">positive Phase 2 study results</a>.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are gaining over 32% following a <a href="https://www.nasdaq.com/press-release/bestgrowthstockscom-issues-comprehensive-analysis-tivic-health-systems-potential">breakdown of its potential catalysts</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is increasing more than 22% with the release of <a href="https://www.nasdaq.com/press-release/longeveronr-presents-study-results-clear-mind-phase-2a-clinical-trial-lomecel-btm">Phase 2a study results</a>.</li>



<li>Pineapple Financial (NYSEMKT:<a href="https://investorplace.com/stock-quotes/papl-stock-quote/">PAPL</a>) shares are rising 22% without any clear news this morning.</li>



<li>Cepton (NASDAQ:<a href="https://investorplace.com/stock-quotes/cptn-stock-quote/">CPTN</a>) stock is climbing over 19% on <a href="https://www.stocktitan.net/news/CPTN/cepton-signs-definitive-agreement-to-be-acquired-by-7cwu0k4o8p93.html">an acquisition agreement</a>.</li>



<li>Ambipar Emergency (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ambi-stock-quote/">AMBI</a>) shares are jumping more than 18% this morning.</li>



<li>BurgerFi (NASDAQ:<a href="https://investorplace.com/stock-quotes/bfi-stock-quote/">BFI</a>) stock is heading over 16% higher as it <a href="https://investorplace.com/2024/07/why-is-burgerfi-international-bfi-stock-up-71-today/">continues a recent rally</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) shares are up more than 15% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>vTv Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtvt-stock-quote/">VTVT</a>) stock is plummeting over 44% after announcing the Food and Drug Administration&nbsp;(FDA) <a href="https://www.nasdaq.com/press-release/vtv-therapeutics-announces-cadisegliatin-program-type-1-diabetes-placed-clinical-hold">placed a clinical hold</a> on one of its trials.</li>



<li>CERo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are diving more than 33% despite a lack of news this morning.</li>



<li>Treasure Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/tgl-stock-quote/">TGL</a>) stock is tumbling over 25% on Monday morning.</li>



<li>LuxUrban Hotels (NASDAQ:<a href="https://investorplace.com/stock-quotes/luxh-stock-quote/">LUXH</a>) shares are taking a more than 17% beating after <a href="https://www.globenewswire.com/news-release/2024/07/27/2919920/0/en/LuxUrban-Hotels-Announces-Pricing-of-Public-Offering-of-Securities.html">pricing a public offering</a>.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is dropping over 11% without any clear news to report.</li>



<li>Phio Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/phio-stock-quote/">PHIO</a>) shares are sliding more than 11% this morning.</li>



<li>Notable Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntbl-stock-quote/">NTBL</a>) stock is decreasing over 10% on Monday morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) shares are falling more than 9% after a Friday rally.</li>



<li>Carbon Revolution (NASDAQ:<a href="https://investorplace.com/stock-quotes/crev-stock-quote/">CREV</a>) stock is slipping over 9% after jumping Friday <a href="https://finance.yahoo.com/news/carbon-revolution-supplies-carbon-fiber-011000695.html">on a wheels deal</a>.</li>



<li>Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-29th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
INVO Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) just reported results for the second quarter of 2024.<ul><li>INVO Bioscience reported earnings per share of -62 cents.</li><li>The company reported revenue of $1.84 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/invo-stock-earnings-invo-bioscience-for-q2-of-2024/">INVO Stock Earnings: INVO Bioscience Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INVO Stock Earnings: INVO Bioscience Reported Results for Q2 2024

INVO BioScience GAAP EPS of -$0.62, revenue of $1.84M

INVO Bioscience ( ($INVO) ) has provided an announcement. INVO Bioscience, Inc. is facing non-compliance with Nasdaq's minimum bid price rule as it...

INVO Bioscience Risks Nasdaq Delisting Amid Stock Price Woes

ACIU

AGBA

AKYA

AMBI

ATNF

AUGX

BZFD

CELC

CERO

CGTX

CLVR

CPTN

CRBG

CREV

CRKN

CYCC

EAST

EYEN

GAME

GDRX

GRRR

GWAV

INVO

JDZG

LAAC

LGVN

LIDR

LIPO

LLAP

LUNR

LUXH

MGNI

MGNX

MYSZ

NOTV

NTBL

NTRB

NUWE

OMER

PAPL

PEGY

PHIO

SEEL

SMFL

STNE

TIVC

TVGN

VCNX

VERV

VTVT

WETH

WISA

WULF

XPON

YIBO

Opinion

Press Releases

Thinking about buying stock in DraftKings, elf Beauty, IONQ, Mountain Crest Acquisition Corp IV, or Invo Bioscience?

INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

Penny Stocks

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

Micro Cap Massively Bid Up Leading Up To Opening Bell

Exploring Emerging Companies with Key Developments Garnering Attention: INBS, INVO, VTAK, RCAT, GCTK

INVO Reports Record First Quarter 2024 Financial Results

INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

DKNG

GCTK

INBS

IONQ

MCAF

RCAT

VTAK

Aethlon Medical

Avinger

Bluejay Diagnostics

Biomerica

Heart Test Laboratories, Inc. - Common Stock

Heart Test Laboratories

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Tech

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

LogicMark

NanoVibronix

ENDRA Life Sciences

NeuroMetrix

Nuwellis

Nexalin Technology

Predictive Oncology

ReShape Lifesciences, Inc. - Common Stock

Reshape Lifesciences

SINTX Techs

Tivic Health Systems, Inc. - Common stock

Tivic Health Systems

Tenon Medical

Venus Concept

Catheter Precision

Xylo Technologies Ltd. - American Depositary Shares

Xylo Technologies

Roth Capital

Maxim Group

INVO BioScience shares are trading higher after the company announced it has closed its merger with NAYA Biosciences.

Comments

INVO Bioscience

Actualités

Dernières nouvelles pour INVO Bioscience (NASDAQ:INVO) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL